NY-ESO-1 Protein Cancer Vaccine with Poly-ICLC and OK-432: Rapid and Strong Induction of NY-ESO-1-specific Immune Responses by Poly-ICLC

Journal of Immunotherapy

Volumn 40, Issue 4, 2017, Pages 140-147

  Takeoka, Tomohira ^a   Nagase, Hirotsugu ^a   Kurose, Koji ^c   Ohue, Yoshihiro ^c   Yamasaki, Makoto ^a   Takiguchi, Shuji ^a   Sato, Eiichi ^e   Isobe, Midori ^c   Kanazawa, Takayuki ^b   Matsumoto, Mitsunobu ^b   Iwahori, Kota ^a   Kawashima, Atsunari ^a   Morimoto Okazawa, Akiko ^a   Nishikawa, Hiroyoshi ^f   Oka, Mikio ^c   Pan, Linda ^g   Venhaus, Ralph ^g   Nakayama, Eiichi ^d   Mori, Masaki ^a   Doki, Yuichiro ^a   Wada, Hisashi ^a   more..

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SHIONOGI AND CO LTD   (Japan)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

^d KAWASAKI UNIVERSITY OF MEDICAL WELFARE   (Japan)

^e TOKYO MEDICAL UNIVERSITY   (Japan)

^f NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

cellular immune response; CT antigen; humoral immune response; toll like receptor

Indexed keywords

CANCER VACCINE; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; GAMMA INTERFERON; MONTANIDE ISA 51; NY ESO 1 ANTIGEN; PICIBANIL;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNIZATION; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DRUG SAFETY; FEMALE; FEVER; HUMAN; IMMUNE RESPONSE; INJECTION SITE REACTION; INTERFERON PRODUCTION; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEROCONVERSION; T LYMPHOCYTE ACTIVATION;

EID: 85016070544     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000162     Document Type: Article

References (31)

1. Temizoz B, Kuroda E, Ishii KJ. Vaccine adjuvants as potential cancer immunotherapeutics. Int Immunol. 2016;28:329-338.
2. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol. 2010;11:373-384.
3. Ingale S, Wolfert MA, Gaekwad J, et al. Robust immune responses elicited by a fully synthetic three-component vaccine. Nat Chem Biol. 2007;3:663-667.
4. CaskeyM, Lefebvre F, Filali-Mouhim A, et al. Synthetic doublestranded RNA induces innate immune responses similar to a live viral vaccine in humans. J ExpMed. 2011;208:2357-2366.
5. Dhodapkar MV, Sznol M, Zhao B, et al. Induction of antigenspecific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med. 2014;6:232ra51.
6. Sabbatini P, Tsuji T, Ferran L, et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res. 2012;18:6497-6508.
7. Tsuji T, Sabbatini P, Jungbluth AA, et al. Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial. Cancer Immunol Res. 2013;1:340-350.
8. Cluff CW. Monophosphoryl lipid a (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv Exp Med Biol. 2009; 667:111-123.
9. Vacchelli E, Martins I, Eggermont A, et al. Trial watch. Oncoimmunology. 2012;1:1557-1576.
10. Krieg AM. Therapeutic potential of toll-like receptor 9 activation. Nat Rev Drug Discov. 2006;5:471-484.
11. Kakimi K, Isobe M, Uenaka A, et al. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. Int J Cancer. 2011;129:2836-2846.
12. Wada H, Isobe M, Kakimi K, et al. Vaccination with NYESO-1 overlapping peptides mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NYESO-1 antigen. J Immunother. 2014;37:84-92.
13. Eikawa S, Kakimi K, Isobe M, et al. Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide. Int J Cancer. 2013;132:345-354.
14. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A. 1997;94: 1914-1918.
15. Gnjatic S, Nishikawa H, Jungbluth AA, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res. 2006;95:1-30.
16. Kawabata R, Wada H, Isobe M, et al. Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients. Int J Cancer. 2007;120:2178-2184.
17. Uenaka A, Wada H, Isobe M, et al. T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NYESO-1 protein. Cancer Immun. 2007;7:9.
18. Kawada J, Wada H, Isobe M, et al. Heteroclitic serological response in esophageal and prostate cancer patients after NYESO-1 protein vaccination. Int J Cancer. 2012;130:584-592.
19. Fujiwara S, Wada H, Kawada J, et al. NY-ESO-1 antibody as a novel tumour marker of gastric cancer. Br J Cancer. 2013; 108:1119-1125.
20. Tsuji K, Hamada T, Uenaka A, et al. Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient. Cancer Immunol Immunother. 2008;57:1429-1437.
21. Wada H, Sato E, Uenaka A, et al. Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination. Int J Cancer. 2008;123:2362-2369.
22. Klein O, Davis ID, McArthur GA, et al. Low-dose cyclophosphamide enhances antigen-specific CD4(+) T cell responses to NY-ESO-1/ISCOMATRIXTM vaccine in patients with advanced melanoma. Cancer Immunol Immunother. 2015;64:507-518.
23. Ennis FA, Cruz J, Jameson J, et al. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Virology. 1999;259:256-261.
24. Butterfield LH. Cancer vaccines. BMJ. 2015;350:h988.
25. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10:909-915.
26. Nakamura Y, Noguchi Y, Satoh E, et al. Spontaneous remission of a non-small cell lung cancer possibly caused by anti-NY-ESO-1 immunity. Lung Cancer. 2009;65:119-122.
27. Verdegaal EME, de Miranda NFCC, Visser M, et al. Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature. 2016;536:91-95.
28. Furness AJ, Quezada SA, Peggs KS. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade? Immunotherapy. 2016;8:763-766.
29. Blank CU, Haanen JB, Ribas A, et al. Cancer Immunology. The cancer immunogram. Science. 2016;352:658-660.
30. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1-10.
31. Fox CB, Friede M, Reed SG, et al. Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants. Subcell Biochem. 2010;53:303-321.